A real-world disproportionality analysis of Everolimus: data mining of the public version of FDA adverse event reporting system
Background: Everolimus is an inhibitor of the mammalian target of rapamycin and is used to treat various tumors. The presented study aimed to evaluate the Everolimus-associated adverse events (AEs) through data mining of the US Food and Drug Administration Adverse Event Reporting System (FAERS).Meth...
保存先:
| 主要な著者: | , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2024-03-01
|
| シリーズ: | Frontiers in Pharmacology |
| 主題: | |
| オンライン･アクセス: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1333662/full |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|